Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Kura Oncology, Inc. - Common Stock
(NQ:
KURA
)
8.060
-0.410 (-4.84%)
Streaming Delayed Price
Updated: 3:31 PM EST, Jan 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kura Oncology, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
January 11, 2026
From
Kura Oncology, Inc.
Via
GlobeNewswire
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
December 31, 2025
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
December 22, 2025
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...
Via
MarketMinute
Topics
ETFs
Economy
Intellectual Property
Kura Scores A Big Win As FDA Approves Its New Leukemia Pill
↗
November 14, 2025
Komzifti wins full FDA approval for NPM1-mutated AML, supported by KOMET-001 data, as Wedbush boosts Kura Oncology's price target to $38.
Via
Benzinga
Kura Oncology Stock Ignites Retail Frenzy After FDA Clears First Daily Pill For Relapsed Leukemia Patients
↗
November 14, 2025
The FDA approved KOMZIFTI, a once-daily oral therapy for relapsed or refractory NPM1-mutated AML.
Via
Stocktwits
Tech's AI Surge Meets Pharma's Resilient Recovery: A Tale of Two Markets in Late 2025
November 05, 2025
The financial markets as of November 5, 2025, present a compelling dichotomy with the technology and pharmaceutical sectors charting distinct yet largely positive courses. While technology continues...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Kura Oncology (NASDAQ:KURA) Reports Q3 2025 Revenue Miss But Narrower-Than-Expected Loss
↗
November 04, 2025
Kura Oncology reported a Q3 2025 revenue miss but a narrower loss. Investors focus on the upcoming FDA decision for its lead drug, ziftomenib, a key catalyst.
Via
Chartmill
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement
↗
October 24, 2025
Via
Stocktwits
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Earnings Scheduled For May 1, 2025
↗
May 01, 2025
Via
Benzinga
Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial
↗
October 24, 2025
Kura Oncology rises after $30M milestone from Kyowa Kirin; Phase 3 ziftomenib dosing and FTI data at ESMO bolster pipeline.
Via
Benzinga
Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data
October 03, 2025
Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant...
Via
MarketMinute
10 Health Care Stocks With Whale Alerts In Today's Session
↗
September 29, 2025
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
September 09, 2025
Via
Benzinga
Uncovering Potential: Kura Oncology's Earnings Preview
↗
April 30, 2025
Via
Benzinga
Earnings Scheduled For February 26, 2025
↗
February 26, 2025
Via
Benzinga
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth
↗
September 04, 2025
Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term profit potential.
Via
Benzinga
This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
September 04, 2025
Via
Benzinga
Evolv Technologies, Precigen, Hesai Group And Other Big Stocks Moving Higher On Friday
↗
August 15, 2025
Via
Benzinga
Kura (KURA) Revenue Drops 61%
↗
August 07, 2025
Via
The Motley Fool
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
April 01, 2025
Via
Benzinga
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe
↗
February 12, 2025
Via
Stocktwits
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
↗
February 06, 2025
Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA submission set for Q2 2025.
Via
Benzinga
These stocks are moving in today's after hours session
↗
February 05, 2025
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
November 21, 2024
Via
Benzinga
Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
↗
November 21, 2024
Via
Benzinga
Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings
↗
November 21, 2024
Via
Benzinga
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
↗
November 21, 2024
Via
Benzinga
Topics
Stocks
Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%
↗
November 21, 2024
Instead of seeking a takeover, the company inked a deal worth up to $1.53 billion for its lead asset.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
